ReviewBest practice & research. Clinical haematology2018
CARs and other T cell therapies for MM: The clinical experience.
Review in Best practice & research. Clinical haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.Journal of hematology & oncology · 2020Pooled it
- The Neurocognitive Impact of CAR T Cell Therapy in Hematological Cancers: A Systematic Review of Cognitive Function, Quality of Life, and Psychological Outcomes.Health science reports · 2025Review
- Current status and future prospects of chimeric antigen receptor-T cell therapy in lymphoma research: A bibliometric analysis.Human vaccines & immunotherapeutics · 2023Article
- CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy.Advanced pharmaceutical bulletin · 2022Review
- B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.Journal of translational medicine · 2022Review
- Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.Frontiers in immunology · 2022Review
- Targeted therapy of multiple myeloma.Exploration of targeted anti-tumor therapy · 2021Review
- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.Leukemia · 2020Review
- Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.Pharmaceutics · 2020Review
- Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma.Frontiers in immunology · 2020Review
- Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies.Frontiers in immunology · 2020Review
- The pharmacologic management of multiple myeloma in older adults.Expert opinion on pharmacotherapy · 2019Review
- Insights on Multiple Myeloma Treatment Strategies.HemaSphere · 2019Review
- Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.Frontiers in immunology · 2019Review
- Multiple Myeloma: What Do We Do About Immunodeficiency?Journal of Cancer · 2019Review
- Biodistribution and sensitive tracking of immune cells with plasmonic gold nanostars.International journal of nanomedicine · 2019Article
- Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.International journal of molecular sciences · 2018Review
- Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma.Frontiers in oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Harnessing the endogenous immune system to eliminate malignant cells has long been an intriguing approach. After considerable success in the treatment of B-cell acute lymphoblastic leukemia, chimeric antigen receptor (CAR)-modified T cells have entered early clinical evaluation in the field of multiple myeloma (MM). The choice of suitable non-CD19 target antigens is challenging and a variety of myeloma-associated surface molecules have been under preclinical investigation. Most recent clinical protocols have focused on targeting B-cell maturation antigen (BCMA), and early results are promising. The trials differ in receptor constructs, patient selection, dosing strategies and conditioning chemotherapy and will thus pave the way to eventually define the optimal parameters. Other sources for autologous T-cell therapy of MM include affinity-enhanced T-cell receptor-modified cells and marrow infiltrating lymphocytes. In summary, adoptive T-cell transfer for the treatment of MM is still in its infancy, but if early response rates indicate durability, will be a paradigm changing therapeutic modality for the treatment of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.